Limitations, agreements, and source contact

CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia · Source last updated 2016-04-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

limitations And Caveats

description

Due to toxicity, study was terminated.

point Of Contact

email

steven_treon@dfci.harvard.edu

organization

DFCI

phone

617 632 2681

title

Steven P. Treon MD PhD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice